公开(公告)号：EP3122346B1

公开(公告)日：2020-07-15

申请号：EP15769367.2

申请日：2015-03-23

申请人： Merck Sharp & Dohme Corp. ,  MSD R & D (China) Co. Ltd.

发明人： MITCHELL, Helen ,  FRALEY, Mark, E. ,  COOKE, Andrew, J. ,  CHEN, Yi-Heng ,  STUMP, Craig, A. ,  ZHANG, Xu-Fang ,  MCCOMAS, Casey, C. ,  SCHIRRIPA, Kathy ,  MCWHERTER, Melody ,  MERCER, Swati, P. ,  BABAOGLU, Kerim ,  MENG, Dongfang ,  WU, Jane ,  LIU, Ping ,  WOOD, Harold, B. ,  BAO, Jianming ,  LI, Chun Sing ,  MAO, Qinghua ,  QI, Zhiqi

IPC分类号： A61K31/166 ,  C07D471/04 ,  A61P35/00

公开(公告)号：EP3122346A2

公开(公告)日：2017-02-01

申请号：EP15769367.2

申请日：2015-03-23

申请人： Merck Sharp & Dohme Corp. ,  MSD R & D (China) Co. Ltd.

发明人： MITCHELL, Helen ,  FRALEY, Mark, E. ,  COOKE, Andrew, J. ,  CHEN, Yi-Heng ,  STUMP, Craig, A. ,  ZHANG, Xu-Fang ,  MCCOMAS, Casey, C. ,  SCHIRRIPA, Kathy ,  MCWHERTER, Melody ,  MERCER, Swati, P. ,  BABAOGLU, Kerim ,  MENG, Dongfang ,  WU, Jane ,  LIU, Ping ,  WOOD, Harold, B. ,  BAO, Jianming ,  LI, Chun Sing ,  MAO, Qinghua ,  QI, Zhiqi

IPC分类号： A61K31/166 ,  C07D471/04

摘要： The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

摘要翻译： 本发明涉及式（I）的六元杂芳基苯甲酰胺化合物，它们是原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛，炎症，癌症，再狭窄，动脉粥样硬化，银屑病 ，血栓形成，与神经生长因子（NGF）受体TrkA的异常活性有关的与髓鞘形成障碍或脱髓鞘有关的疾病，病症，损伤或功能障碍或疾病或病症。

公开(公告)号：EP2350010B1

公开(公告)日：2014-03-26

申请号：EP09741173.0

申请日：2009-10-26

申请人： Merck Sharp & Dohme Corp.

发明人： BERGMAN, Jeffrey, M. ,  COLEMAN, Paul, J. ,  MATTERN, Mamio Christa ,  MERCER, Swati, P. ,  REGER, Thomas, S. ,  ROECKER, Anthony, J.

IPC分类号： C07D213/81 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14

CPC分类号： C07D401/04 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14

公开(公告)号：EP3122345A2

公开(公告)日：2017-02-01

申请号：EP15769224.5

申请日：2015-03-23

申请人： Merck Sharp & Dohme Corp.

发明人： MITCHELL, Helen ,  FRALEY, Mark, E. ,  COOKE, Andrew, J. ,  STUMP, Craig, A. ,  CHEN, Yi Heng ,  BESHORE, Douglas, C. ,  ZHANG, Xu-Fang ,  MCCOMAS, Casey, C. ,  SCHIRRIPA, Kathy ,  MCWHERTER, Melody ,  MERCER, Swati, P. ,  MOORE, Keith, P. ,  LIU, Ping ,  WOOD, Harold, B. ,  LI, Chun Sing ,  MAO, Qinghua

IPC分类号： A61K31/166

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

摘要： The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

摘要翻译： 本发明涉及式（I）的双环杂芳基苯甲酰胺化合物，其是原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛，炎症，癌症，再狭窄，动脉粥样硬化，牛皮癣， 与神经生长因子（NGF）受体TrkA的异常活动相关的血栓形成，疾病，障碍，损伤或与异常髓鞘或脱髓鞘相关的疾病或障碍。

公开(公告)号：EP2349267A1

公开(公告)日：2011-08-03

申请号：EP09824043.5

申请日：2009-10-26

申请人： Merck Sharp & Dohme Corp.

发明人： COLEMAN, Paul, J. ,  COX, Christopher, D. ,  MERCER, Swati, P. ,  ROECKER, Anthony, J. ,  SCHREIER, John, D.

IPC分类号： A61K31/4439 ,  A61K31/405 ,  C07D333/66

CPC分类号： A61K31/405 ,  A61K31/4439 ,  C07D333/66

摘要： The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

公开(公告)号：EP2323985B1

公开(公告)日：2017-01-11

申请号：EP09791168.9

申请日：2009-08-05

申请人： Merck Sharp & Dohme Corp.

发明人： COLEMAN, Paul, J. ,  MERCER, Swati, P. ,  REGER, Thomas, S. ,  ROECKER, Anthony, J.

IPC分类号： C07D213/82

CPC分类号： C07D213/82

公开(公告)号：EP2349267B1

公开(公告)日：2014-06-25

申请号：EP09824043.5

申请日：2009-10-26

申请人： Merck Sharp & Dohme Corp.

发明人： COLEMAN, Paul, J. ,  COX, Christopher, D. ,  MERCER, Swati, P. ,  ROECKER, Anthony, J. ,  SCHREIER, John, D.

IPC分类号： A61K31/4439 ,  A61K31/405 ,  C07D333/66 ,  A61P25/20

CPC分类号： A61K31/405 ,  A61K31/4439 ,  C07D333/66

公开(公告)号：EP2421370A1

公开(公告)日：2012-02-29

申请号：EP10767743.7

申请日：2010-04-22

申请人： Merck Sharp & Dohme Corp.

发明人： MERCER, Swati, P. ,  ROECKER, Anthony, J. ,  WILLIAMS, Theresa ,  ZHANG, Xu-Fang

IPC分类号： A01N43/82 ,  A61K31/41

CPC分类号： C07D413/04 ,  C07D413/14

摘要： The present invention is directed to 2-alkylpiperidines which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

摘要翻译： 本发明涉及2-代烷基哌啶，其为代谢型谷氨酸受体的正变构调节剂，特别是mGluR5受体，并且其可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及其中代谢型谷氨酸受体为 参与其中。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。

公开(公告)号：EP2350010A1

公开(公告)日：2011-08-03

申请号：EP09741173.0

申请日：2009-10-26

申请人： Merck Sharp & Dohme Corp.

发明人： BERGMAN, Jeffrey, M. ,  COLEMAN, Paul, J. ,  MATTERN, Mamio Christa ,  MERCER, Swati, P. ,  REGER, Thomas, S. ,  ROECKER, Anthony, J.

IPC分类号： C07D213/81 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14

CPC分类号： C07D401/04 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14

摘要： The present invention is directed to isonicotinamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

公开(公告)号：EP2184981A1

公开(公告)日：2010-05-19

申请号：EP08795115.8

申请日：2008-08-07

申请人： Merck Sharp & Dohme Corp.

发明人： BERGMAN, Jeffrey, M. ,  COLEMAN, Paul, J. ,  FRALEY, Mark, E. ,  MERCER, Swati, P. ,  REGER, Thomas, S. ,  ROECKER, Anthony, J. ,  STEEN, Justin, T.

IPC分类号： A01N37/16 ,  A61K31/519 ,  A61K31/16

CPC分类号： C07D213/82 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  C07D401/04 ,  C07D401/14

摘要： The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.